Breast Cancer Research Foundation

Recent papers from Breast Cancer Research Foundation

1. Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE projectESMO Open · 2026
2. Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cellsJournal of Clinical Investigation · 2026
3. Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell deathJournal for ImmunoTherapy of Cancer · 2026
4. Thyroid Cancer Incidence in North-East Spain, 2002–2021: A Population-Based StudyCancers · 2026
5. Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible PatientsAnnals of Surgical Oncology · 2026
6. Advances in locoregional surgical treatment of de-novo stage IV breast cancer: a reviewFrontiers in Oncology · 2026
7. ntSynt-viz: Visualizing synteny patterns across multiple genomesJournal of Evolutionary Biology · 2026
8. Municipal-level correlates and spatial variations of Korea’s national cancer screening program in 2018 and 2022: focus on weighted ordinary least squares regression and local indicators of spatial associationBMC Public Health · 2026
9. 69 Spatial Proteomics Profiling Identifies Prognostic Biomarkers in Papillary Renal Cell CarcinomaThe Oncologist · 2026
10. Efficacy and Safety of Local Tranexamic Acid in Rhytidectomy: A Systematic Review and Meta-analysisPlastic & Reconstructive Surgery Global Open · 2026
11. Combined Pathological Response and PEPI Score Improves Long-term Prognostic Stratification in HR-positive Breast Cancer Following Neoadjuvant Endocrine TherapyIn Vivo · 2026
12. Prognostic impact of HER2-low versus HER2-zero expression by hormone receptor status in early breast cancer: a retrospective cohort studyBMC Cancer · 2026
13. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCRJournal of Clinical Oncology · 2026
14. Peak Uptake Value on Positron Emission Mammography Addresses Biopsy Sampling Limitations in Stratifying Proliferative Activity of Malignant Non-Mass EnhancementBritish Journal of Radiology · 2026
15. HER2DX in early-stage HER2-positive breast cancer: a review of clinical utilityESMO Open · 2026
16. UnnaturalAmino Acid Substitutions to Improve In VivoGRPR-Targeting Capability of [68Ga]Ga-SP01011 for CancerImagingMolecular Pharmaceutics · 2026
17. Variations in histopathological and molecular subtypes between primary breast carcinoma and associated liver metastatic lesionsFrontiers in Oncology · 2026
18. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancerTherapeutic Advances in Medical Oncology · 2026
19. Characterisation of a novel p53 mutation (p53N263Tfs*7) associated with li-fraumeni syndromeBMC Cancer · 2026
20. In Vitro Degradation Behavior of the Mg-Cu Alloy in Simulated Gastric Fluid and Its Bioactivity against H. pylori and Gastric Cancer CellsACS Biomaterials Science & Engineering · 2026